Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Terbuch, A; Adiprasito, JB; Stiegelbauer, V; Seles, M; Klec, C; Pichler, GP; Resel, M; Posch, F; Lembeck, AL; Stöger, H; Szkandera, J; Pummer, K; Bauernhofer, T; Hutterer, GC; Gerger, A; Stotz, M; Pichler, M.
MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Int J Mol Sci. 2018; 19(10):
Doi: 10.3390/ijms19103130
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Pichler Martin
- Terbuch Angelika
- Co-Autor*innen der Med Uni Graz
- Adiprasito Jan Basri
- Bauernhofer Thomas
- Gerger Armin
- Hutterer Georg
- Klec Christiane
- Pichler Georg
- Posch Florian
- Pummer Karl
- Resel Margit
- Seles Maximilian
- Stiegelbauer Verena
- Stöger Herbert
- Stotz Michael
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Metastatic testicular germ cell tumors (TGCTs) are a potentially curable disease by administration of risk-adapted cytotoxic chemotherapy. Nevertheless, a disease-relapse after curative chemotherapy needs more intensive salvage chemotherapy and significantly worsens the prognosis of TGCT patients. Circulating tumor markers (β-subunit of human chorionic gonadotropin (β-HCG), alpha-Fetoprotein (AFP), and Lactate Dehydrogenase (LDH)) are frequently used for monitoring disease recurrence in TGCT patients, though they lack diagnostic sensitivity and specificity. Increasing evidence suggests that serum levels of stem cell-associated microRNAs (miR-371a-3p and miR-302/367 cluster) are outperforming the traditional tumor markers in terms of sensitivity to detect newly diagnosed TGCT patients. The aim of this study was to investigate whether these miRNAs are also informative in detection of disease recurrence in TGCT patients after curative first line therapy. For this purpose, we measured the serum levels of miR-371a-3p and miR-367 in 52 samples of ten TGCT patients at different time points during disease relapse and during salvage chemotherapy. In our study, miR-371a-3p levels in serum samples with proven disease recurrence were 13.65 fold higher than levels from the same patients without evidence of disease (p = 0.014). In contrast, miR-367 levels were not different in these patient groups (p = 0.985). In conclusion, miR-371a-3p is a sensitive and potentially novel biomarker for detecting disease relapse in TGCT patients. This promising biomarker should be investigated in further large prospective trials.
- Find related publications in this database (Keywords)
- microRNAs
- diagnosis
- testicular cancer